Cargando…
Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases
Respiratory viral pathogens like influenza and coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused outbreaks leading to millions of deaths. Vaccinations are, to date, the best and most economical way to control such outbreaks and have been highly successful...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society for Microbiology
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597982/ https://www.ncbi.nlm.nih.gov/pubmed/34788128 http://dx.doi.org/10.1128/CMR.00123-21 |
_version_ | 1784600710238699520 |
---|---|
author | Iyer, Shalini Yadav, Rajesh Agarwal, Smriti Tripathi, Shashank Agarwal, Rachit |
author_facet | Iyer, Shalini Yadav, Rajesh Agarwal, Smriti Tripathi, Shashank Agarwal, Rachit |
author_sort | Iyer, Shalini |
collection | PubMed |
description | Respiratory viral pathogens like influenza and coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused outbreaks leading to millions of deaths. Vaccinations are, to date, the best and most economical way to control such outbreaks and have been highly successful for several pathogens. Currently used vaccines for respiratory viral pathogens are primarily live attenuated or inactivated and can risk reversion to virulence or confer inadequate immunity. The recent trend of using potent biomolecules like DNA, RNA, and protein antigenic components to synthesize vaccines for diseases has shown promising results. Still, it remains challenging to translate due to their high susceptibility to degradation during storage and after delivery. Advances in bioengineering technology for vaccine design have made it possible to control the physicochemical properties of the vaccines for rapid synthesis, heightened antigen presentation, safer formulations, and more robust immunogenicity. Bioengineering techniques and materials have been used to synthesize several potent vaccines, approved or in trials, against coronavirus disease 2019 (COVID-19) and are being explored for influenza, SARS, and Middle East respiratory syndrome (MERS) vaccines as well. Here, we review bioengineering strategies such as the use of polymeric particles, liposomes, and virus-like particles in vaccine development against influenza and coronaviruses and the feasibility of adopting these technologies for clinical use. |
format | Online Article Text |
id | pubmed-8597982 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | American Society for Microbiology |
record_format | MEDLINE/PubMed |
spelling | pubmed-85979822021-12-02 Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases Iyer, Shalini Yadav, Rajesh Agarwal, Smriti Tripathi, Shashank Agarwal, Rachit Clin Microbiol Rev Review Respiratory viral pathogens like influenza and coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused outbreaks leading to millions of deaths. Vaccinations are, to date, the best and most economical way to control such outbreaks and have been highly successful for several pathogens. Currently used vaccines for respiratory viral pathogens are primarily live attenuated or inactivated and can risk reversion to virulence or confer inadequate immunity. The recent trend of using potent biomolecules like DNA, RNA, and protein antigenic components to synthesize vaccines for diseases has shown promising results. Still, it remains challenging to translate due to their high susceptibility to degradation during storage and after delivery. Advances in bioengineering technology for vaccine design have made it possible to control the physicochemical properties of the vaccines for rapid synthesis, heightened antigen presentation, safer formulations, and more robust immunogenicity. Bioengineering techniques and materials have been used to synthesize several potent vaccines, approved or in trials, against coronavirus disease 2019 (COVID-19) and are being explored for influenza, SARS, and Middle East respiratory syndrome (MERS) vaccines as well. Here, we review bioengineering strategies such as the use of polymeric particles, liposomes, and virus-like particles in vaccine development against influenza and coronaviruses and the feasibility of adopting these technologies for clinical use. American Society for Microbiology 2021-11-17 /pmc/articles/PMC8597982/ /pubmed/34788128 http://dx.doi.org/10.1128/CMR.00123-21 Text en Copyright © 2021 American Society for Microbiology. https://doi.org/10.1128/ASMCopyrightv2All Rights Reserved (https://doi.org/10.1128/ASMCopyrightv2) . https://doi.org/10.1128/ASMCopyrightv2This article is made available via the PMC Open Access Subset for unrestricted noncommercial re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic. |
spellingShingle | Review Iyer, Shalini Yadav, Rajesh Agarwal, Smriti Tripathi, Shashank Agarwal, Rachit Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases |
title | Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases |
title_full | Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases |
title_fullStr | Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases |
title_full_unstemmed | Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases |
title_short | Bioengineering Strategies for Developing Vaccines against Respiratory Viral Diseases |
title_sort | bioengineering strategies for developing vaccines against respiratory viral diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8597982/ https://www.ncbi.nlm.nih.gov/pubmed/34788128 http://dx.doi.org/10.1128/CMR.00123-21 |
work_keys_str_mv | AT iyershalini bioengineeringstrategiesfordevelopingvaccinesagainstrespiratoryviraldiseases AT yadavrajesh bioengineeringstrategiesfordevelopingvaccinesagainstrespiratoryviraldiseases AT agarwalsmriti bioengineeringstrategiesfordevelopingvaccinesagainstrespiratoryviraldiseases AT tripathishashank bioengineeringstrategiesfordevelopingvaccinesagainstrespiratoryviraldiseases AT agarwalrachit bioengineeringstrategiesfordevelopingvaccinesagainstrespiratoryviraldiseases |